JP2024514090A5 - - Google Patents

Info

Publication number
JP2024514090A5
JP2024514090A5 JP2023560010A JP2023560010A JP2024514090A5 JP 2024514090 A5 JP2024514090 A5 JP 2024514090A5 JP 2023560010 A JP2023560010 A JP 2023560010A JP 2023560010 A JP2023560010 A JP 2023560010A JP 2024514090 A5 JP2024514090 A5 JP 2024514090A5
Authority
JP
Japan
Prior art keywords
methyl
cyclopropanecarboxamide
triazole
carboxamide
methoxy
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2023560010A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024514090A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2022/021815 external-priority patent/WO2022212181A1/en
Publication of JP2024514090A publication Critical patent/JP2024514090A/ja
Publication of JP2024514090A5 publication Critical patent/JP2024514090A5/ja
Pending legal-status Critical Current

Links

JP2023560010A 2021-03-29 2022-03-24 6-(シクロプロパンカルボキサミド)-4-((2-メトキシ-3-(1-メチル-1h-1,2,4-トリアゾール-3-イル)フェニル)アミノ)-n-(メチル-d3)ピリダジン-3-カルボキサミドの結晶形態 Pending JP2024514090A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202163167504P 2021-03-29 2021-03-29
US63/167,504 2021-03-29
PCT/US2022/021815 WO2022212181A1 (en) 2021-03-29 2022-03-24 Crystal forms of 6-(cyclopropanecarboxamido)-4-((2-methoxy-3-(1-methyl-1h-1,2,4-triazol-3-yl)phenyl)amino)-n-(methyl-d3)pyridazine-3-carboxamide

Publications (2)

Publication Number Publication Date
JP2024514090A JP2024514090A (ja) 2024-03-28
JP2024514090A5 true JP2024514090A5 (cg-RX-API-DMAC10.html) 2025-04-01

Family

ID=81308277

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023560010A Pending JP2024514090A (ja) 2021-03-29 2022-03-24 6-(シクロプロパンカルボキサミド)-4-((2-メトキシ-3-(1-メチル-1h-1,2,4-トリアゾール-3-イル)フェニル)アミノ)-n-(メチル-d3)ピリダジン-3-カルボキサミドの結晶形態

Country Status (6)

Country Link
US (1) US20240190845A1 (cg-RX-API-DMAC10.html)
EP (1) EP4313974A1 (cg-RX-API-DMAC10.html)
JP (1) JP2024514090A (cg-RX-API-DMAC10.html)
KR (1) KR20230163469A (cg-RX-API-DMAC10.html)
CN (1) CN117377667A (cg-RX-API-DMAC10.html)
WO (1) WO2022212181A1 (cg-RX-API-DMAC10.html)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
LT3601268T (lt) * 2017-03-30 2021-05-25 Bristol-Myers Squibb Company 6-(ciklopropanamido)-4-((2-metoksi-3-(1-metil-1h-1,2,4-triazol-3-il)fenil)amino)-n-(metil-d3)piridazino-3-karboksamido gavimo būdas
JP2024529763A (ja) * 2021-08-20 2024-08-08 ブリストル-マイヤーズ スクイブ カンパニー 6-(シクロプロパンカルボキサミド)-4-((2-メトキシ-3-(1-メチル-1h-1,2,4-トリアゾール-3-イル)フェニル)アミノ)-n-(メチル-d3)ピリダジン-3-カルボキサミドの結晶体
EP4713315A1 (en) * 2023-05-15 2026-03-25 Alivus Life Sciences Limited Process for the preparation of deucravacitinib, and crystalline forms thereof

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HRP20220766T1 (hr) * 2012-11-08 2022-09-16 Bristol-Myers Squibb Company Amidom-supstituirani heterociklički spojevi korisni kao modulatori il-12, il-23 i/ili ifn alfa odgovora
LT3601268T (lt) * 2017-03-30 2021-05-25 Bristol-Myers Squibb Company 6-(ciklopropanamido)-4-((2-metoksi-3-(1-metil-1h-1,2,4-triazol-3-il)fenil)amino)-n-(metil-d3)piridazino-3-karboksamido gavimo būdas
CN111032646B (zh) * 2017-08-01 2023-01-03 施万生物制药研发Ip有限责任公司 作为jak激酶抑制剂的吡唑并和三唑并双环化合物
CN118994118A (zh) * 2018-05-31 2024-11-22 百时美施贵宝公司 化合物的结晶形式
US11357775B2 (en) * 2019-04-30 2022-06-14 Celgene Corporation Combination therapies comprising apremilast and Tyk2 inhibitors
US12570637B2 (en) * 2019-06-12 2026-03-10 Bristol-Myers Squibb Company Crystalline salt forms 6-(cyclopropanecarboxamido)-4-((2-methoxy-3-(1-methyl-1H-1,2,4-triazol-3-yl)phenyl)amino)-n-(methyld3) pyridazine-3-carboxamide
CN114787152A (zh) * 2019-12-27 2022-07-22 苏州科睿思制药有限公司 一种bms-986165晶型及其制备方法和用途

Similar Documents

Publication Publication Date Title
JP2024505063A5 (cg-RX-API-DMAC10.html)
JP2020512380A5 (cg-RX-API-DMAC10.html)
TWI406661B (zh) 4-甲基-n-〔3-(4-甲基-咪唑-1-基)-5-三氟甲基-苯基〕-3-(4-吡啶-3-基-嘧啶-2基胺基)-苯甲醯胺之結晶型
JP2005503386A5 (cg-RX-API-DMAC10.html)
JP2023036708A5 (cg-RX-API-DMAC10.html)
PL208708B1 (pl) Polimorficzne formy chlorowodorku 1-4-(5-cyjanoindolo-3 -ylo) butylo-4- (2-karbamoilobenzofurano-5-ylo) piperazyny, sposób ich otrzymywania, ich zastosowanie w terapii zaburzeń medycznych i zawierające je kompozycje farmaceutyczne
JP3665053B2 (ja) 純結晶形態の5−クロロ−3−(4−メタンスルホニルフェニル)−6’−メチル−[2,3’]ビピリジニルおよび合成方法
JP2021523918A5 (cg-RX-API-DMAC10.html)
JP2025511847A5 (cg-RX-API-DMAC10.html)
AU2004291282A1 (en) Pyridazin-3 (2H) -one derivatives and their use as PDE4 inhibitors
JP2022551316A5 (cg-RX-API-DMAC10.html)
JP2009521414A5 (cg-RX-API-DMAC10.html)
JP2022533340A5 (cg-RX-API-DMAC10.html)
JP2024540922A5 (cg-RX-API-DMAC10.html)
AU2001264804A1 (en) 5-chloro-3-(4-methanesulfonylphenyl)-6'-methyl- [2,3']bipyridinyl in pure crystalline form and process for synthesis
JP2024521412A5 (cg-RX-API-DMAC10.html)
JP2022540922A5 (cg-RX-API-DMAC10.html)
JP2024529763A5 (cg-RX-API-DMAC10.html)
JP2022544272A5 (cg-RX-API-DMAC10.html)
JP2025102940A5 (cg-RX-API-DMAC10.html)
TW202444341A (zh) 萘胺類粒線體自噬誘導劑的固體形式、其製備方法、藥物組合物和用途
JP2018522945A5 (cg-RX-API-DMAC10.html)
CA2447878C (en) 5-chloro-3-(4-methanesulfonylphenyl)-6'-methyl-[2,3']bipyridinyl in pure crystalline form and process for synthesis
JP2024515770A5 (cg-RX-API-DMAC10.html)
JP2022540678A5 (cg-RX-API-DMAC10.html)